Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6911698 | 1.00 | CHRM1 (0.91) | CHRM1CHRM4 | |
| SCHEMBL6915120 | 1.00 | CHRM1 (0.91) | CHRM1CHRM4 | |
| SCHEMBL6912246 | 0.99 | CHRM1 (0.90) | CHRM1CHRM4 | |
| SCHEMBL6915565 | 0.95 | CHRM1 (0.88) | CHRM1CHRM4 | |
| SCHEMBL8189336 | 0.95 | CHRM1 (1.00) | CHRM1CHRM4 | |
| SCHEMBL8189299 | 0.95 | CHRM1 (1.00) | CHRM1CHRM4 | |
| SCHEMBL8196563 | 0.94 | CHRM1 (1.00) | CHRM1CHRM4 | |
| Oxalic Acid SCHEMBL7619270 | 0.94 | CHRM1 (0.79) | CHRM1CHRM4 | |
| Tazomeline SCHEMBL7615741 | 0.94 | CHRM1 (0.79) | CHRM1CHRM4 | |
| Oxalic Acid SCHEMBL7642910 | 0.94 | CHRM1 (0.79) | CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023172240-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC (US) | 2023-09-14 | — | — | WO | claimed |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-10-17 | — | — | US | claimed |
| US-20180050008-A1 | OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-02-22 | — | — | US | claimed |
| US-20180050018-A1 | PERIPHERAL-ANTICHOLINERGIC MUSCARINIC AGONIST COMBINATION | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-02-22 | — | — | US | claimed |
| EP-3265128-A1 | OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION | Chase Pharmaceuticals Corporation (US) | 2018-01-10 | — | — | EP | claimed |
| EP-3265466-A1 | PERIPHERAL-ANTICHOLINERGIC MUSCARINIC AGONIST COMBINATION | Chase Pharmaceuticals Corporation (US) | 2018-01-10 | — | — | EP | claimed |
| US-20160375001-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2016-12-29 | — | — | US | claimed |
| WO-2016144719-A1 | OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION | CHASE THOMAS N (US) | 2016-09-15 | — | — | WO | claimed |
| WO-1996025042-A1 | TRANSDERMAL FORMULATION | ELI LILLY AND COMPANY (US) | 1996-08-22 | — | — | WO | claimed |
| EP-0727209-A2 | Transdermal formulation of a compound having muscarinic activity | ELI LILLY AND COMPANY (US) | 1996-08-21 | — | — | EP | claimed |
| WO-1996014066-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1996-05-17 | — | — | WO | claimed |
| WO-1996013168-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1996-05-09 | — | — | WO | claimed |
| EP-0709095-A2 | Method for treating anxiety using a tetrahydropyridine or azabicyclic oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| US-5488056-A | 1,2,5-THIADIAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-01-30 | — | — | US | claimed |
| EP-0384288-B1 | Piperidine compounds and their preparation and use | NOVO NORDISK AS (DK) | 1995-05-24 | — | — | EP | claimed |
| WO-1995005174-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | claimed |
| US-5041455-A | Stimulants of cognitive function in mammals | NOVO NORDISK A/S (DK) | 1991-08-20 | — | — | US | claimed |
| EP-0384288-A2 | Piperidine compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1990-08-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050018-A1 | PERIPHERAL-ANTICHOLINERGIC MUSCARINIC AGONIST COMBINATION | CHRM3, CHRM2, CHRM4 | CHRM1 7/4885CHRM4 3/4885 |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | CHRM1 5/4885CHRM4 3/4885 |
| US-20160375001-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | CHRM1 5/4885CHRM4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.